TIFFANY FONTE: Open Payments
NPI 1255779443 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,107 in 126 payments from 28 companies in 2025. Trend: 2023 $3,217 · 2024 $3,728 · 2025 $3,107
Food & beverage: $3,107
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation | 10 | $381 |
| ABIOMED | 2 | $276 |
| Alnylam Pharmaceuticals Inc. | 5 | $213 |
| Novartis Pharmaceuticals Corporation | 9 | $206 |
| Amgen Inc. | 25 | $200 |
| Merck Sharp & Dohme LLC | 8 | $194 |
| BridgeBio Pharma, Inc. | 6 | $189 |
| E.R. Squibb & Sons, L.L.C. | 8 | $171 |
| PFIZER INC. | 5 | $110 |
| AngioDynamics, Inc. | 2 | $107 |
Products named: AMVUTTRA, LEQVIO, REPATHA, Attruby, WATCHMAN FLX, WINREVAIR, CAMZYOS, EkoSonic.
Industry payments across NV — which companies pay providers there.
